Biocytogen Sets 27 Aug 2026 Board Meeting to Approve H1 2026 Results and Mull Interim Dividend

Bulletin Express08-17

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that its board of directors will convene on 27 August 2026. The agenda centers on two items:

1. Approval and publication of the consolidated interim results for the six months ended 30 June 2026. 2. Deliberation on the declaration of an interim dividend, if any.

The meeting timetable underscores the company’s commitment to timely financial disclosure and potential capital returns. The board is chaired by Shen Yuelei, who also serves as chief executive officer and executive director. The current board structure comprises two executive directors, three non-executive directors, three independent non-executive directors, and one employee director.

The announcement, released on 17 August 2026, did not provide preliminary financial figures; detailed results will be available following board approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178275211?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-17 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178275211","market":"us","top_or_hot":-1,"title":"Biocytogen Sets 27 Aug 2026 Board Meeting to Approve H1 2026 Results and Mull Interim Dividend","media":"Bulletin Express","content":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that its board of directors will convene on 27 August 2026. The agenda centers on two items:</p>\n<p>1. Approval and publication of the consolidated interim results for the six months ended 30 June 2026.  \n2. Deliberation on the declaration of an interim dividend, if any.</p>\n<p>The meeting timetable underscores the company’s commitment to timely financial disclosure and potential capital returns. The board is chaired by Shen Yuelei, who also serves as chief executive officer and executive director. The current board structure comprises two executive directors, three non-executive directors, three independent non-executive directors, and one employee director.</p>\n<p>The announcement, released on 17 August 2026, did not provide preliminary financial figures; detailed results will be available following board approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen Sets 27 Aug 2026 Board Meeting to Approve H1 2026 Results and Mull Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen Sets 27 Aug 2026 Board Meeting to Approve H1 2026 Results and Mull Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-17 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that its board of directors will convene on 27 August 2026. The agenda centers on two items:</p>\n<p>1. Approval and publication of the consolidated interim results for the six months ended 30 June 2026.  \n2. Deliberation on the declaration of an interim dividend, if any.</p>\n<p>The meeting timetable underscores the company’s commitment to timely financial disclosure and potential capital returns. The board is chaired by Shen Yuelei, who also serves as chief executive officer and executive director. The current board structure comprises two executive directors, three non-executive directors, three independent non-executive directors, and one employee director.</p>\n<p>The announcement, released on 17 August 2026, did not provide preliminary financial figures; detailed results will be available following board approval.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1178275211","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178275211","pubTimestamp":1786956243,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that its board of directors will convene on 27 August 2026. The agenda centers on two items: 1. Approval and publication of the consolidated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"Biocytogen 定于 2026 年 8 月 27 日召开董事会会议，批准 2026 年上半年业绩并考虑中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that its board of directors will convene on 27 August 2026. The agenda centers on two items:\n1. Approval and publication of the consolidated interim results for the six months ended 30 June 2026.  \n2. Deliberation on the declaration of an interim dividend, if any.\nThe meeting timetable underscores the company’s commitment to timely financial disclosure and potential capital returns. The board is chaired by Shen Yuelei, who also serves as chief executive officer and executive director. The current board structure comprises two executive directors, three non-executive directors, three independent non-executive directors, and one employee director.\nThe announcement, released on 17 August 2026, did not provide preliminary financial figures; detailed results will be available following board approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178275211","isCrawlerRequest":true}